This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Telmisartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so blood can flow more easily.
Angiotensin II Receptor antagonist
Telmisartan is a non-peptide angiotensin-ll receptor antagonist. Angiotensin-ll is formed from angiotensin-l in a reaction catalyzed by angiotensin converting enzyme. Angiotensin-ll is the principal agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin-ll by selectively blocking the binding of angiotensin-ll to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin-ll synthesis. Telmisartan has much greater affinity (>3,000 fold) for the AT1 receptor than for the AT2 receptor. Because Telmisartan does not inhibit ACE (kininase-ll), it does not affect the response to bradykinin. Telmisartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.
Adult: Initially, 40 mg once daily. Max: 80 mg/day,
NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect.
Co-administration with aliskiren with Telmisartan: in patients with diabetes should be avoided.
Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation. Hepatic insufficiency, biliary obstruction, renal impairment, renaly artery stenosis. Correct vol depletion before initiating treatment. Monitor serum K levels regularly, esp in elderly & renally impaired patients.
URTI, dizziness, back pain, sinusitis, pharyngitis & diarrhoea. Slight elevations in liver enzymes. Rarely angioedema, rash, pruritus & urticaria.
avoid use during pregnancy & lactation.
The most likely manifestation of overdosage with Telmisartan tablets would be hypotension, dizziness and tachycardia; bradycardia, increase in serum creatinine and acute renal failure could occur from parasympathetic (vagal) stimulation.
Do not store above 30°C. Protect from light and high humidity. Keep out of the reach of children.
.png&w=384&q=75)